1887

Microbiology Society logo

Volume 170, Issue 11

Agarooligosaccharides as a novel concept in prebiotics: selective inhibition of and while preserving Bifidobacteria, Lactobacillales , and inhibiting Lachnospiraceae Open Access

Abstract

Recent studies have linked to inflammatory bowel disease and to various cancers. Agarooligosaccharides (AOS), derived from the acid hydrolysis of agar, have shown significant inhibitory effects on the growth of and at concentrations of 0.1 and 0.2%, respectively. RNA sequencing and quantitative reverse-transcription PCR analyses revealed the downregulation of fatty acid biosynthesis genes ( genes) in these bacteria when exposed to 0.1% AOS. Furthermore, AOS treatment altered the fatty acid composition of cell membranes, increasing medium-chain saturated fatty acids (C8, C10) and C18 fatty acids while reducing long-chain fatty acids (C14, C16). In contrast, no significant growth inhibition was observed in several strains of Bifidobacteria and Lactobacillales at AOS concentrations of 0.2 and 2%, respectively. Co-culture experiments with and in 0.2% AOS resulted in dominating the population, constituting over 96% post-incubation. studies using mice demonstrated a significant reduction in the Lachnospiraceae family, to which belongs, following AOS administration. Quantitative PCR also showed lower levels of the gene, potentially associated with immune disorders, in the AOS group. These findings suggest that AOS may introduce a novel concept in prebiotics by selectively inhibiting potentially pathogenic bacteria while preserving beneficial bacteria such as Bifidobacteria and Lactobacillales.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): agarooligosaccharides , Bifidobacteria , fab , Fusobacterium nucleatum , Lactobacillales and Ruminococcus gnavus
© 2024 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/micro/10.1099/mic.0.001510
2024-11-29
2024-12-03
Loading full text...

Full text loading...

/deliver/fulltext/micro/170/11/mic001510.html?itemId=/content/journal/micro/10.1099/mic.0.001510&mimeType=html&fmt=ahah

References

  1. Colella M, Charitos IA, Ballini A, Cafiero C, Topi S et al. Microbiota revolution: how gut microbes regulate our lives. World J Gastroenterol 2023; 29:4368–4383 [View Article]
     [Google Scholar]
  2. Zhu Y, Ouyang Z, Du H, Wang M, Wang J et al. New opportunities and challenges of natural products research: when target identification meets single-cell multiomics. Acta Pharm Sin B 2022; 12:4011–4039 [View Article]
     [Google Scholar]
  3. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995; 125:1401–1412 [View Article]
     [Google Scholar]
  4. Gibson GR, Scott KP, Rastall RA, Tuohy KM, Hotchkiss A et al. Dietary prebiotics: current status and new definition. Food Sci Technol Bull Funct Foods 2010; 7:1–19 [View Article]
     [Google Scholar]
  5. Chen X, Fu X, Huang L, Xu J, Gao X. Agar oligosaccharides: a review of preparation, structures, bioactivities and application. Carbohydr Polym 2021; 265:118076 [View Article]
     [Google Scholar]
  6. Jiang C, Cheng D, Liu Z, Sun J, Mao X. Advances in agaro-oligosaccharides preparation and bioactivities for revealing the structure-function relationship. Food Res Int 2021; 145:110408 [View Article]
     [Google Scholar]
  7. Zhang X, Aweya JJ, Huang ZX, Kang ZY, Bai ZH et al. In vitro fermentation of Gracilaria lemaneiformis sulfated polysaccharides and its agaro-oligosaccharides by human fecal inocula and its impact on microbiota. Carbohydr Polym 2020; 234:115894 [View Article]
     [Google Scholar]
  8. Yun EJ, Lee AR, Kim JH, Cho KM, Kim KH. 3, 6-anhydro-l-galactose, a rare sugar from agar, a new anticariogenic sugar to replace xylitol. Food Chem 2017; 221:976–983 [View Article]
     [Google Scholar]
  9. Rubinstein MR, Wang X, Liu W, Hao Y, Cai G et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its fada adhesin. Cell host microbe 2013; 14:195–206 [View Article]
     [Google Scholar]
  10. Yu S, Yun EJ, Kim DH, Park SY, Kim KH. Anticariogenic activity of agarobiose and agarooligosaccharides derived from red macroalgae. J Agric Food Chem 2019; 67:7297–7303 [View Article]
     [Google Scholar]
  11. Bell A, Brunt J, Crost E, Vaux L, Nepravishta R et al. Elucidation of a sialic acid metabolism pathway in mucus-foraging Ruminococcus gnavus unravels mechanisms of bacterial adaptation to the gut. Nat Microbiol 2019; 4:2393–2404 [View Article]
     [Google Scholar]
  12. Hall AB, Yassour M, Sauk J, Garner A, Jiang X et al. A novel Ruminococcus gnavus clade enriched in inflammatory bowel disease patients. Genome Med 2017; 9:103 [View Article]
     [Google Scholar]
  13. Henke MT, Kenny DJ, Cassilly CD, Vlamakis H, Xavier RJ et al. Ruminococcus gnavus, a member of the human gut microbiome associated with Crohn’s disease, produces an inflammatory polysaccharide. Proc Natl Acad Sci USA 2019; 116:12672–12677 [View Article]
     [Google Scholar]
  14. Nagasaka M, Fujii T, Funasaka K, Ohno E, Hirooka Y et al. Assessment of risk for immune and psychiatric disorders using qpcr-based monitoring of the nan gene in gut microbiota: A non-invasive approach. Microbiol Res J Int 2024107–119
     [Google Scholar]
  15. Togo AH, Diop A, Bittar F, Maraninchi M, Valero R et al. Correction to: description of Mediterraneibacter massiliensis, gen. nov., sp. nov., a new genus isolated from the gut microbiota of an obese patient and reclassification of Ruminococcus faecis, Ruminococcus lactaris, Ruminococcus torques, Ruminococcus gnavus and Clostridium glycyrrhizinilyticum as Mediterraneibacter faecis comb. nov., Mediterraneibacter lactaris comb. nov., Mediterraneibacter torques comb. nov., Mediterraneibacter gnavus comb. nov. and Mediterraneibacter glycyrrhizinilyticus comb. nov. Antonie van Leeuwenhoek 2018; 111:2129–2130 [View Article]
     [Google Scholar]
  16. Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 2012; 22:299–306 [View Article]
     [Google Scholar]
  17. Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012; 22:292–298 [View Article]
     [Google Scholar]
  18. Wu J, Li Q, Fu X. Fusobacterium nucleatum contributes to the carcinogenesis of colorectal cancer by inducing inflammation and suppressing host immunity. Transl Oncol 2019; 12:846–851 [View Article]
     [Google Scholar]
  19. Barrons R, Tassone D. Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review. C lin Ther 2008; 30:453–468 [View Article]
     [Google Scholar]
  20. Lim HJ, Shin HS. Antimicrobial and immunomodulatory effects of Bifidobacterium strains: a review. J Microbiol Biotechnol 2020; 30:1793–1800 [View Article]
     [Google Scholar]
  21. Reid G, Burton J. Use of Lactobacillus to prevent infection by pathogenic bacteria. Microbes Infect 2002; 4:319–324 [View Article]
     [Google Scholar]
  22. Valdés L, Salazar N, González S, Arboleya S, Ríos-Covián D et al. Selection of potential probiotic bifidobacteria and prebiotics for elderly by using in vitro faecal batch cultures. Eur Food Res Technol 2017; 243:157–165 [View Article]
     [Google Scholar]
  23. Al-Sheraji SH, Ismail A, Manap MY, Mustafa S, Yusof RM et al. Prebiotics as functional foods: a review. J Funct Foods 2013; 5:1542–1553 [View Article]
     [Google Scholar]
  24. Blay GL, Lacroix C, Zihler A, Fliss I. In vitro inhibition activity of nisin A, nisin Z, pediocin PA-1 and antibiotics against common intestinal bacteria. Lett Appl Microbiol 2007; 45:252–257 [View Article]
     [Google Scholar]
  25. Shirai I, Sakai T, Shiba K, Uzuhashi Y, Karasawa K. Agaro-oligosaccharides prevent myostatin hyperexpression and myosin heavy chain protein degradation in C2C12 myotubes induced by tumor necrosis factor-α. Cellbio 2018; 7:23–34 [View Article]
     [Google Scholar]
  26. Fujii T, Tochio T, Endo A. Ribotype-dependent growth inhibition and promotion by erythritol in Cutibacterium acnes. J Cosmet Dermatol 2022; 21:5049–5057 [View Article]
     [Google Scholar]
  27. Panchal VV, Griffiths C, Mosaei H, Bilyk B, Sutton JAF et al. Evolving MRSA: high-level β-lactam resistance in Staphylococcus aureus is associated with RNA polymerase alterations and fine tuning of gene expression. PLoS Pathog 2020; 16:e1008672 [View Article] [PubMed]
     [Google Scholar]
  28. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001; 25:402–408 [View Article]
     [Google Scholar]
  29. Mutha NVR, Mohammed WK, Krasnogor N, Tan GYA, Choo SW et al. Transcriptional responses of Streptococcus gordonii and Fusobacterium nucleatum to coaggregation. Mol Oral Microbiol 2018; 33:450–464 [View Article]
     [Google Scholar]
  30. Furet JP, Firmesse O, Gourmelon M, Bridonneau C, Tap J et al. Comparative assessment of human and farm animal faecal microbiota using real-time quantitative PCR. FEMS Microbiol Ecol 2009; 68:351–362 [View Article]
     [Google Scholar]
  31. Lee ZM-P, Bussema C, Schmidt TM. rrnDB: documenting the number of rRNA and tRNA genes in bacteria and archaea. Nucleic Acids Res 2009; 37:D489–D493 [View Article]
     [Google Scholar]
  32. Yu S, Choi I-G, Yun EJ, Kim KH. High substrate specificity of 3, 6-anhydro-l-galactose dehydrogenase indicates its essentiality in the agar catabolism of a marine bacterium. Process Biochem 2018; 64:130–135 [View Article]
     [Google Scholar]
  33. Heath RJ, White SW, Rock CO. Lipid biosynthesis as a target for antibacterial agents. Prog Lipid Res 2001; 40:467–497 [View Article]
     [Google Scholar]
  34. Eijkelkamp BA, Begg SL, Pederick VG, Trapetti C, Gregory MK et al. Arachidonic acid stress impacts pneumococcal fatty acid homeostasis. Front Microbiol 2018; 9:813 [View Article]
     [Google Scholar]
  35. Rogers PD, Liu TT, Barker KS, Hilliard GM, English BK et al. Gene expression profiling of the response of Streptococcus pneumoniae to penicillin. J Antimicrob Chemother 2007; 59:616–626 [View Article]
     [Google Scholar]
  36. Martin PK, Li T, Sun D, Biek DP, Schmid MB. Role in cell permeability of an essential two-component system in Staphylococcus aureus. J Bacteriol 1999; 181:3666–3673 [View Article]
     [Google Scholar]
  37. Afzal M, Ahmed H, Siddique MH, Muzammil S, Azeem F et al. Exploring the impact of paracetamol on the transcriptome of Streptococcus pneumoniae D39. J King Saud Univ Sci 2022; 34:102282 [View Article]
     [Google Scholar]
  38. Masuda K, Sakai N, Nakamura K, Yoshioka S, Ayabe T. Bactericidal activity of mouse α-defensin cryptdin-4 predominantly affects noncommensal bacteria. J Innate Immun 2011; 3:315–326 [View Article]
     [Google Scholar]
  39. Yao J, Rock CO. Exogenous fatty acid metabolism in bacteria. Biochimie 2017; 141:30–39 [View Article]
     [Google Scholar]
  40. Hennessy AA, Ross P, Devery R, Stanton C. Bifidobacterially produced, c18: 3 and c18: 4 conjugated fatty acids exhibit in vitro anti-carcinogenic and anti-microbial activity. Eur J Lipid Sci Technol 2016; 118:1743–1758 [View Article]
     [Google Scholar]
  41. Enoki T, Okuda S, Kudo Y, Takashima F, Sagawa H et al. Oligosaccharides from agar inhibit pro-inflammatory mediator release by inducing heme oxygenase 1. Biosci Biotechnol Biochem 2010; 74:766–770 [View Article]
     [Google Scholar]
  42. Higashimura Y, Naito Y, Takagi T, Mizushima K, Hirai Y et al. Oligosaccharides from agar inhibit murine intestinal inflammation through the induction of heme oxygenase-1 expression. J Gastroenterol 2013; 48:897–909 [View Article]
     [Google Scholar]
  43. Higashimura Y, Baba Y, Inoue R, Takagi T, Mizushima K et al. Agaro-oligosaccharides regulate gut microbiota and adipose tissue accumulation in mice. J Nutr Sci Vitaminol 2017; 63:269–276 [View Article]
     [Google Scholar]
  44. Liu X, Mao B, Gu J, Wu J, Cui S et al. Blautia —a new functional genus with potential probiotic properties?. Gut Microbes 2021; 13:1–21 [View Article]
     [Google Scholar]
  45. Moens F, De Vuyst L. Inulin-type fructan degradation capacity of clostridium cluster IV and xiva butyrate-producing colon bacteria and their associated metabolic outcomes. Benef Microbes 2017; 8:473–490 [View Article]
     [Google Scholar]
  46. Reilly NA, Sonnet F, Dekkers KF, Kwekkeboom JC, Sinke L et al. Oleic acid triggers metabolic rewiring of T cells poising them for T helper 9 differentiation. iScience 2024; 27:109496 [View Article]
     [Google Scholar]
  47. Takeuchi T, Kameyama K, Miyauchi E, Nakanishi Y, Kanaya T et al. Fatty acid overproduction by gut commensal microbiota exacerbates obesity. Cell Metab 2023; 35:361–375 [View Article] [PubMed]
     [Google Scholar]
  48. Francisco V, Pino J, Campos-Cabaleiro V, Ruiz-Fernández C, Mera A et al. Obesity, fat mass and immune system: role for leptin. Front Physiol 2018; 9:640 [View Article]
     [Google Scholar]
  49. Zhou Q, Zhang Y, Wang X, Yang R, Zhu X et al. Gut bacteria Akkermansia is associated with reduced risk of obesity: evidence from the american gut project. Nutr Metab 2020; 17:1–9 [View Article]
     [Google Scholar]
  50. Christensen L, Vuholm S, Roager HM, Nielsen DS, Krych L et al. Prevotella abundance predicts weight loss success in healthy, overweight adults consuming a whole-grain diet ad libitum: a post hoc analysis of A 6-wk randomized controlled trial. J Nutr 2019; 149:2174–2181 [View Article]
     [Google Scholar]
  51. Tavella T, Rampelli S, Guidarelli G, Bazzocchi A, Gasperini C et al. Elevated gut microbiome abundance of. Gut Microbes 2021; 13:1–19 [View Article]
     [Google Scholar]
  52. Hirano R, Sakanaka M, Yoshimi K, Sugimoto N, Eguchi S et al. Next-generation prebiotic promotes selective growth of bifidobacteria, suppressing clostridioides difficile. Gut Microbes 2021; 13:1973835 [View Article]
     [Google Scholar]
  53. Endo A, Nakamura S, Konishi K, Nakagawa J, Tochio T. Variations in prebiotic oligosaccharide fermentation by intestinal lactic acid bacteria. Int J Food Sci Nutr 2016; 67:125–132 [View Article]
     [Google Scholar]
  54. Ose R, Hirano K, Maeno S, Nakagawa J, Salminen S et al. The ability of human intestinal anaerobes to metabolize different oligosaccharides: novel means for microbiota modulation. Anaerobe 2018; 51:110–119 [View Article]
     [Google Scholar]
  55. Tochio T, Kitaura Y, Nakamura S, Sugawa C, Takahashi M et al. An alteration in the cecal microbiota composition by feeding of 1-kestose results in a marked increase in the cecal butyrate content in rats. PLoS One 2016; 11:e0166850 [View Article]
     [Google Scholar]
/content/journal/micro/10.1099/mic.0.001510
Loading
Agarooligosaccharides as a novel concept in prebiotics: selective inhibition of Ruminococcus gnavus and Fusobacterium nucleatum while preserving Bifidobacteria, Lactobacillales in vitro, and inhibiting Lachnospiraceae in vivo
Microbiology 170, 001510 (2024); https://doi.org/10.1099/mic.0.001510
/content/journal/micro/10.1099/mic.0.001510
/content/journal/micro/10.1099/mic.0.001510
Loading

Data & Media loading...

Supplements

Supplementary material 1

EXCEL

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error